Viking Therapeutics (NASDAQ: VKTX) has captured the attention of investors, with its stock price skyrocketing over 400% in ...

Viking Therapeutics (NASDAQ: VKTX), a biotech stock that has rocketed to prominence thanks to one of its investigational ...

I'm bullish on Viking Therapeutics' weight-loss drug, but warn of risks and competition ahead. Click here to read my most ...

While it might not perfectly follow in the larger biotech's footsteps, TERN-601 has the potential to be one of the safer, ...

Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Two stocks at opposite ends of the spectrum are Amgen (NASDAQ: AMGN), the healthcare behemoth, and Viking Therapeutics (NASDAQ: VKTX), which doesn't have an approved drug but hopes a new GLP-1 drug ...

The general mood among these heavyweight investors is divided, with 57% leaning bullish and 26% bearish. Among these notable ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $70.47 which represents a slight increase of $2.31 or 3.39% from the prior close of $68.16. The stock opened at $69.5 and ...

Viking Therapeutics (VKTX) has received a new Buy rating, initiated by J.P. Morgan analyst, Hardik Parikh. Hardik Parikh has given his Buy ...

Leerink Partners Biopharma Private Company Connect Format: 1x1 Investor Meetings Date/Time: Tuesday, October 22 and Wednesday, October 23 Location: Virtual ...